Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

<b>MEMBER'S LAST NAME</b>	:	MEMBER'S FIRST	NAME:	
	view (e.g., chart notes o	or lab data, to support th	<ul> <li>Attach any additional documents</li> <li>authorization request). In</li> </ul>	
				URGENT
MEMBER INFORMATIO	N			
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRT	H:	
STREET ADDRESS:				
CITY:		STATE:	ZIP CODE:	
PATIENT INSURANCE	D NUMBER:	1		
☐ MALE ☐ FEMALE	HEIGHT (IN/CM):	WEIGHT (LB/KG):	ALLERGIES:	
FOLLOWING LINK: PRIMPATIENT'S AUTHORIZE	METHERAPEUTICS.CO  D REPRESENTATIVE	OM/NOPP (IF APPLICABLE):	I CAN BE FOUND AT THE	
AUTHORIZED REPRESE	NTATIVE'S PHONE N	UMBER:		
PRESCRIBER INFORMA	ATION			
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIAL	.TY:	EMAIL ADDRE	EMAIL ADDRESS:	
NPI NUMBER:		DEA NUMBER:	DEA NUMBER:	
PHONE NUMBER:		FAX NUMBER:	FAX NUMBER:	
STREET ADDRESS:				
CITY:		STATE:	ZIP CODE:	
REQUESTER (if different than prescriber):		OFFICE CONT	OFFICE CONTACT PERSON:	
		•		
MEDICATION OR MEDI	CAL DISPENSING INF	ORMATION		
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REF	QUANTITY:	
☐ NEW THERAPY	RENEWAL	IF RENEWAL: DATE T	l.	
DURATION OF THERAF	Y (SPECIFIC DATES):			
Continued on next page				

©2017-2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 7.1.25 CAT009



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST	NAME:				
1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION?  ☐ YES (if yes, complete below) ☐ NO						
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:				
2. LIST DIAGNOSES:		ICD-10:				
<ul> <li>☐ Ankylosing spondylitis</li> <li>☐ Axial spondyloarthropathy</li> <li>☐ Juvenile idiopathic arthritis</li> <li>☐ Plaque psoriasis</li> <li>☐ Psoriatic arthritis</li> <li>☐ Rheumatoid arthritis</li> </ul>						
Other diagnosis:Code(s):	ICD-10					
3. REQUIRED CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION OF THE PR		ELEVANT CLINICAL INFORMATION				
Is patient going to be using drug in combination with a clinical trial?   Yes No Select if Enbrel is prescribed by one of the following specialists:  Dermatologist Rheumatologist						
Will Enbrel be used in combination with a biologic response modifier or an immunomodulator agent (such as but not limited to Kineret, Rituxan, Remicade, Orencia, Cimzia, Humira, Simponi, Actemra, Stelara, Rinvoq or Xeljanz)? □ Yes □ No						
Has the patient tried and had an inadequate response to a three month trial of the <u>biosimilar</u> for Humira- <u>adalimumab-aacf</u> ?   — Yes — No Please submit documentation.						
Does patient have a absolute contrai  ☐ No Please submit documentation.	ndication to the biosimilar for	Humira- adalimumab-aacf? □ Yes				
Has the patient tried and had an inaction of the contract of t						
Does patient have a absolute contrai aazg)? □ Yes □ No Please submit		Actemra, Tyenne(tocilizumab-				
Has the patient tried and had an inadequate response to a 4- month trial of the <u>biosimilar</u> for Stelara- Otulfi(ustekinumb-aauz)? □ Yes □ No Please submit documentation.						

Prime THERAPEUTICS\*

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAME:	
Does patient have a absolute contraindication to the biosimilar for Stelara-Otulfi(ustekinumb-aa use)    Ves    No Please submit documentation.	<u>uz</u> )?
For ankylosing spondylitis/ axial spondyloarthropathy, also answer the following: Has the patient had an adequate trial and failure of at least TWO non-steroidal anti-inflammatory agents (NSAIDs)?   Yes  No (Provide NSAIDs and dates of service)	,
Has the patient tried methotrexate? □ Yes □ No (Provide dates of service)	
Has the patient tried sulfasalazine? □ Yes □ No (Provide dates of service)	
For juvenile idiopathic arthritis, also answer the following: Has the patient tried and had an inadequate response or intolerance to an oral disease modifying anti-rheumatic agent [e.g., methotrexate, azathioprine (Imuran), auranofin (Ridaura), hydroxychloroquine (Plaquenil), sulfasalazine (Azulfidine), or leflunomide (Arava)]? □ Yes □ N  Is the patient unable to take a non-biologic DMARD due to chronic liver disease (such as chronic hepatitis, fatty liver, nonalcoholic steatohepatitis/NASH, or elevated liver enzymes)? □ Yes □ N  If "no" to the above question, provide the rationale explaining why the patient cannot take the prerequisite DMARDs:	o C
For plaque psoriasis, also answer the following:  Does the patient have plaques covering 10% or more of the body surface area (BSA)?   Does the patient have plaques covering < 10% of BSA, but with involvement of palms, soles, here and neck, or genitalia which causes disruption of normal activities   Yes   No  Has the patient tried and had an inadequate response or intolerance to at least one of the follow therapies: methotrexate, cyclosporine, and/or phototherapy?   Yes   No  If "no" to the above question, provide the rationale explaining why the patient cannot take the prerequisite agents:	ad
For psoriatic arthritis, also answer the following:  Has the patient tried and had an inadequate response or intolerance to an oral disease modifying anti-rheumatic agent [e.g., methotrexate, azathioprine (Imuran), auranofin (Ridaura), hydroxychloroquine (Plaquenil), sulfasalazine (Azulfidine), or leflunomide (Arava)]?	•



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:
hepatitis, fatty liver, nonalcoholic Is the patient unable to take non- a female of childbearing potentia	n-biologic DMARD due to chronic liver disease (such as chronic steatohepatitis/NASH, or elevated liver enzymes)?   Biologic DMARD because they are a male of fatherhood potential or leaven and leaven
	inadequate response or intolerance to methotrexate or another oral cagent (DMARD) [e.g., azathioprine (Imuran), auranofin (Ridaura), or
hepatitis, fatty liver, nonalcoholic	n-biologic DMARD due to chronic liver disease such as chronic steatohepatitis/NASH, or elevated enzymes?   Biologic DMARD because they are a male of fatherhood potential or
Reauthorization:	et, answer the following questions:
Select if Enbrel is prescribed by o  Dermatologist Rheumatologist	one of the following specialists:
	on with another biologic or immunomodulatory agent (such as but emicade, Orencia, Cimzia, Humira, Simponi, Actemra, Stelara,
	e a positive clinical response and remission of disease is <sup>*</sup> □ Yes □ No*Please provide documentation (e.g., chart notes) ponse.
Are there any other comments, d information the physician feels is	iagnoses, symptoms, medications tried or failed, and/or any other important to this review?



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	_ MEMBER'S FIRST NAME:	
Please note: Not all drugs/diagnosis are covered of	on all plans. This request may be denied unless all	
required information is received.	. ,	
<b>ATTESTATION:</b> I attest the information provided in	is true and accurate to the best of my knowledge. I	
·	Group or its designees may perform a routine audit and	
·	fy the accuracy of the information reported on this form.	
request the meaner memater necessary to verify	y are accuracy or are information reported on the form	
Prescriber Signature or Electronic I.D. Verificat	tion: Date:	
<b>CONFIDENTIALITY NOTICE:</b> The documents accomments	companying this transmission contain confidential health	Ī
	the intended recipient, you are hereby notified that any	
0 , 1 0 ,	reliance on the contents of these documents is strictly	
	error, please notify the sender immediately (via return	
FAX) and arrange for the return or destruction of the		
, ,		
EAY THIS FOI	NPM TO: 800-424-7640	

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program
Attn: CP-4201

P.O. Box 64811 St. Paul, MN 55164-0811 **Phone**: 877-228-7909